These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16891456

  • 1. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D.
    Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
    [Abstract] [Full Text] [Related]

  • 2. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D.
    Biochemistry; 2007 May 22; 46(20):5941-50. PubMed ID: 17455910
    [Abstract] [Full Text] [Related]

  • 3. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.
    Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, Ross D.
    Mol Pharmacol; 2009 Jul 22; 76(1):163-72. PubMed ID: 19364812
    [Abstract] [Full Text] [Related]

  • 4. ES936 stimulates DNA synthesis in HeLa cells independently on NAD(P)H:quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK.
    González-Aragón D, Alcaín FJ, Ariza J, Jódar L, Barbarroja N, López-Pedrera C, Villalba JM.
    Chem Biol Interact; 2010 Jul 30; 186(2):174-83. PubMed ID: 20433816
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
    Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, Ross D.
    Biochemistry; 2001 Dec 18; 40(50):15135-42. PubMed ID: 11735396
    [Abstract] [Full Text] [Related]

  • 6. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo.
    Gustafson DL, Siegel D, Rastatter JC, Merz AL, Parpal JC, Kepa JK, Ross D, Long ME.
    J Pharmacol Exp Ther; 2003 Jun 18; 305(3):1079-86. PubMed ID: 12649308
    [Abstract] [Full Text] [Related]

  • 7. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
    Dehn DL, Siegel D, Swann E, Moody CJ, Ross D.
    Mol Pharmacol; 2003 Sep 18; 64(3):714-20. PubMed ID: 12920209
    [Abstract] [Full Text] [Related]

  • 8. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.
    Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, Weydert CJ, Domann FE, Oberley LW.
    Cancer Res; 2003 Sep 01; 63(17):5513-20. PubMed ID: 14500388
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
    Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ.
    J Med Chem; 2007 Nov 15; 50(23):5780-9. PubMed ID: 17944451
    [Abstract] [Full Text] [Related]

  • 10. NAD(P)H:quinone oxidoreductase 1-compromised human bone marrow endothelial cells exhibit decreased adhesion molecule expression and CD34+ hematopoietic cell adhesion.
    Zhou H, Dehn D, Kepa JK, Siegel D, Scott DE, Tan W, Ross D.
    J Pharmacol Exp Ther; 2010 Jul 15; 334(1):260-8. PubMed ID: 20378716
    [Abstract] [Full Text] [Related]

  • 11. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger.
    Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D.
    Mol Pharmacol; 2004 May 15; 65(5):1238-47. PubMed ID: 15102952
    [Abstract] [Full Text] [Related]

  • 12. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D, Shieh B, Yan C, Kepa JK, Ross D.
    J Pharmacol Exp Ther; 2011 Mar 15; 336(3):874-80. PubMed ID: 21156818
    [Abstract] [Full Text] [Related]

  • 13. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1509-16. PubMed ID: 11377380
    [Abstract] [Full Text] [Related]

  • 14. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 15. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
    Kolossov VL, Ponnuraj N, Beaudoin JN, Leslie MT, Kenis PJ, Gaskins HR.
    Biochem Biophys Res Commun; 2017 Jan 29; 483(1):680-686. PubMed ID: 27986568
    [Abstract] [Full Text] [Related]

  • 16. Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress.
    Lewis A, Ough M, Li L, Hinkhouse MM, Ritchie JM, Spitz DR, Cullen JJ.
    Clin Cancer Res; 2004 Jul 01; 10(13):4550-8. PubMed ID: 15240547
    [Abstract] [Full Text] [Related]

  • 17. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger.
    Zhu H, Jia Z, Mahaney JE, Ross D, Misra HP, Trush MA, Li Y.
    Cardiovasc Toxicol; 2007 Jul 01; 7(3):202-11. PubMed ID: 17901563
    [Abstract] [Full Text] [Related]

  • 18. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
    Nolan KA, Zhao H, Faulder PF, Frenkel AD, Timson DJ, Siegel D, Ross D, Burke TR, Stratford IJ, Bryce RA.
    J Med Chem; 2007 Dec 13; 50(25):6316-25. PubMed ID: 17999461
    [Abstract] [Full Text] [Related]

  • 19. Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen.
    Moffit JS, Aleksunes LM, Kardas MJ, Slitt AL, Klaassen CD, Manautou JE.
    Toxicology; 2007 Feb 12; 230(2-3):197-206. PubMed ID: 17188792
    [Abstract] [Full Text] [Related]

  • 20. Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner.
    Park EJ, Min KJ, Choi KS, Kwon TK.
    Exp Cell Res; 2014 Apr 15; 323(1):144-154. PubMed ID: 24462458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.